NICE has today (15 October 2020) issued draft guidance which now recommends siponimod (also called Mayzent and made by Novartis) for treating secondary progressive multiple sclerosis (MS).
If we can get it and if it works for you personally, who knows?
My MS nurse referred me back to a consultant because Siponimod was being considered for SP. I had a consultation just before lockdown and was told Nice had rejected it so I’m very pleased they have now recommended it.
I have just had an MRI my second since diagnosis so I wait with bated breath the outcome and a further consultation. Watch this space